Subsequently, a phase II, randomized, double-blind, placebo-controlled, crossover clinical trial by Guttmann-Gruber et al. (2022) [75] in patients with dystrophic EB and COL7A1 gene mutations demonstrated significant results. The gene discussed is COL7A1; the disease is epidermolysis bullosa.